IMI ramps up COVID fund
The funding pot of the Innovation Medicines Initiative has been boosted to €117m. IMI has also selected eight projects to fund.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 287 entries already.
Entries by Uta Mommert
Agriculture ministers commit to global trade rules
Ministers from 72 countries came together at the Berlin Agriculture Ministers’ conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based free trade.
HepaRegeniX: €11m for liver disease treatment
HepaRegeniX has raised €11m in a Series B. The biotech company will use the proceeds to bring its compound targeting chronic liver disease to the clinic.
Iberian biotech newcomer
The geographical proximity of Spain’s Northwestern region Galicia to Northern Portugal is a key factor for the birth of the new bioregion CT-Bio. This achievement looks forward to improving business competitiveness and the consolidation of the biotech and life sciences sector internationally.
Cellestia: €20m to get to Phase II
Basel-based biopharma company Cellestia Biotech AG has successfully closed a Series B financing round, raising a total of CHF 20 million.
€7.34m for cancer vaccine developer
Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.
Vaximm goes East for cancer vaccine deal
Swiss-German biotech Vaximm is teaming up with Tokyo-based AI specialist NEC to advance personalised neoantigen cancer vaccines.
Abcam buys Expedeon’s immunology business
Expedeon has sold its immunology and proteomics business activities to global life sciences company Abcam. Abcam is paying €120m in cash for the business.
UniQure looking to raise US$200m
Dutch gene therapy company UniQure has launched a US$200m stock offering on Nasdaq.
MS: Polpharma joins forces with Sandoz
Polpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible for the development, manufacturing and supply of the collaboration biosimilar, which is currently in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).